Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches

Sandra Perdomo, Patrice H Avogbe, Matthieu Foll, Behnoush Abedi-Ardekani, Violeta Lescher Facciolla, Devasena Anantharaman, Priscilia Chopard, Florence Le Calvez-Kelm, Marta Vilensky, Jerry Polesel, Ivana Holcatova, Lorenzo Simonato, Cristina Canova, Pagona Lagiou, James D McKay, Paul Brennan

Research output: Contribution to journalArticle

Abstract

The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection ofTP53mutations in plasma and oral rinses without previous knowledge of mutational status in tumor samples. Targeted sequencing in 5 genes identified ctDNA mutations in plasma among 42% of HNSCC cases, 67% of who were early stage cases. No association was found between ctDNA mutation detection and overall survival. Sequencing of the entire coding region of theTP53gene resulted in identification ofTP53mutations in 76% of tumor cases. However, concordance of mutation detection was low between tumor, oral rinses (11%) and plasma (2,7%) samples. Identification of 5 pathogenicTP53mutations in oral rinses from 3 non-cancer controls gives additional evidence of mutation occurrence in individuals without a diagnosed cancer and presents an additional challenge for the development of ctDNA diagnostic assays.

Original languageEnglish
Pages (from-to)72621-72632
Number of pages12
JournalOncotarget
Volume8
Issue number42
DOIs
Publication statusPublished - Sep 22 2017

Fingerprint

Head and Neck Neoplasms
DNA
Neoplasms
Mutation
South America
Early Diagnosis
Neck
Biomarkers
Head

Keywords

  • Journal Article

Cite this

Perdomo, S., Avogbe, P. H., Foll, M., Abedi-Ardekani, B., Facciolla, V. L., Anantharaman, D., ... Brennan, P. (2017). Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget, 8(42), 72621-72632. https://doi.org/10.18632/oncotarget.20004

Circulating tumor DNA detection in head and neck cancer : evaluation of two different detection approaches. / Perdomo, Sandra; Avogbe, Patrice H; Foll, Matthieu; Abedi-Ardekani, Behnoush; Facciolla, Violeta Lescher; Anantharaman, Devasena; Chopard, Priscilia; Calvez-Kelm, Florence Le; Vilensky, Marta; Polesel, Jerry; Holcatova, Ivana; Simonato, Lorenzo; Canova, Cristina; Lagiou, Pagona; McKay, James D; Brennan, Paul.

In: Oncotarget, Vol. 8, No. 42, 22.09.2017, p. 72621-72632.

Research output: Contribution to journalArticle

Perdomo, S, Avogbe, PH, Foll, M, Abedi-Ardekani, B, Facciolla, VL, Anantharaman, D, Chopard, P, Calvez-Kelm, FL, Vilensky, M, Polesel, J, Holcatova, I, Simonato, L, Canova, C, Lagiou, P, McKay, JD & Brennan, P 2017, 'Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches', Oncotarget, vol. 8, no. 42, pp. 72621-72632. https://doi.org/10.18632/oncotarget.20004
Perdomo S, Avogbe PH, Foll M, Abedi-Ardekani B, Facciolla VL, Anantharaman D et al. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget. 2017 Sep 22;8(42):72621-72632. https://doi.org/10.18632/oncotarget.20004
Perdomo, Sandra ; Avogbe, Patrice H ; Foll, Matthieu ; Abedi-Ardekani, Behnoush ; Facciolla, Violeta Lescher ; Anantharaman, Devasena ; Chopard, Priscilia ; Calvez-Kelm, Florence Le ; Vilensky, Marta ; Polesel, Jerry ; Holcatova, Ivana ; Simonato, Lorenzo ; Canova, Cristina ; Lagiou, Pagona ; McKay, James D ; Brennan, Paul. / Circulating tumor DNA detection in head and neck cancer : evaluation of two different detection approaches. In: Oncotarget. 2017 ; Vol. 8, No. 42. pp. 72621-72632.
@article{cdc1328ada3546d088c1d2552569efc2,
title = "Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches",
abstract = "The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection ofTP53mutations in plasma and oral rinses without previous knowledge of mutational status in tumor samples. Targeted sequencing in 5 genes identified ctDNA mutations in plasma among 42{\%} of HNSCC cases, 67{\%} of who were early stage cases. No association was found between ctDNA mutation detection and overall survival. Sequencing of the entire coding region of theTP53gene resulted in identification ofTP53mutations in 76{\%} of tumor cases. However, concordance of mutation detection was low between tumor, oral rinses (11{\%}) and plasma (2,7{\%}) samples. Identification of 5 pathogenicTP53mutations in oral rinses from 3 non-cancer controls gives additional evidence of mutation occurrence in individuals without a diagnosed cancer and presents an additional challenge for the development of ctDNA diagnostic assays.",
keywords = "Journal Article",
author = "Sandra Perdomo and Avogbe, {Patrice H} and Matthieu Foll and Behnoush Abedi-Ardekani and Facciolla, {Violeta Lescher} and Devasena Anantharaman and Priscilia Chopard and Calvez-Kelm, {Florence Le} and Marta Vilensky and Jerry Polesel and Ivana Holcatova and Lorenzo Simonato and Cristina Canova and Pagona Lagiou and McKay, {James D} and Paul Brennan",
year = "2017",
month = "9",
day = "22",
doi = "10.18632/oncotarget.20004",
language = "English",
volume = "8",
pages = "72621--72632",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "42",

}

TY - JOUR

T1 - Circulating tumor DNA detection in head and neck cancer

T2 - evaluation of two different detection approaches

AU - Perdomo, Sandra

AU - Avogbe, Patrice H

AU - Foll, Matthieu

AU - Abedi-Ardekani, Behnoush

AU - Facciolla, Violeta Lescher

AU - Anantharaman, Devasena

AU - Chopard, Priscilia

AU - Calvez-Kelm, Florence Le

AU - Vilensky, Marta

AU - Polesel, Jerry

AU - Holcatova, Ivana

AU - Simonato, Lorenzo

AU - Canova, Cristina

AU - Lagiou, Pagona

AU - McKay, James D

AU - Brennan, Paul

PY - 2017/9/22

Y1 - 2017/9/22

N2 - The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection ofTP53mutations in plasma and oral rinses without previous knowledge of mutational status in tumor samples. Targeted sequencing in 5 genes identified ctDNA mutations in plasma among 42% of HNSCC cases, 67% of who were early stage cases. No association was found between ctDNA mutation detection and overall survival. Sequencing of the entire coding region of theTP53gene resulted in identification ofTP53mutations in 76% of tumor cases. However, concordance of mutation detection was low between tumor, oral rinses (11%) and plasma (2,7%) samples. Identification of 5 pathogenicTP53mutations in oral rinses from 3 non-cancer controls gives additional evidence of mutation occurrence in individuals without a diagnosed cancer and presents an additional challenge for the development of ctDNA diagnostic assays.

AB - The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection ofTP53mutations in plasma and oral rinses without previous knowledge of mutational status in tumor samples. Targeted sequencing in 5 genes identified ctDNA mutations in plasma among 42% of HNSCC cases, 67% of who were early stage cases. No association was found between ctDNA mutation detection and overall survival. Sequencing of the entire coding region of theTP53gene resulted in identification ofTP53mutations in 76% of tumor cases. However, concordance of mutation detection was low between tumor, oral rinses (11%) and plasma (2,7%) samples. Identification of 5 pathogenicTP53mutations in oral rinses from 3 non-cancer controls gives additional evidence of mutation occurrence in individuals without a diagnosed cancer and presents an additional challenge for the development of ctDNA diagnostic assays.

KW - Journal Article

U2 - 10.18632/oncotarget.20004

DO - 10.18632/oncotarget.20004

M3 - Article

C2 - 29069814

VL - 8

SP - 72621

EP - 72632

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 42

ER -